ALK1-BMPRII agonism by clustering bispecific antibodies treats hereditary hemorrhagic telangiectasia
Sima Qutaina, Haitian Zhao, Zhiming Wang, Andy Sullivan, Melissa L. Geddie, Raminderjeet Kaur, Hong Wei Tian, Huan Yue, Xin Wang, Siyang Guo, Margherita Bruni, Erica Christen, Fabien Campagne, Helen M. Arthur, Patrick André, Philippe Marambaud
This study develops bispecific antibodies that activate the ALK1-BMPRII pathway, reducing AVMs and improving symptoms in HHT mouse models.
bioRxiv · Aug 13, 2025 · PreprintCell Biology